Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
28
05
2019
revised:
10
09
2019
accepted:
17
09
2019
entrez:
20
2
2020
pubmed:
20
2
2020
medline:
20
2
2020
Statut:
epublish
Résumé
While classical nodal mantle cell lymphoma (cMCL) is often associated with involvement of multiple extranodal sites, isolated extranodal disease (ED) at the time of diagnosis is a rare event; data on the outcome of these forms are lacking. On behalf of the European MCL Network, we conducted a retrospective analysis on the clinical characteristics and outcomes of MCL presenting with isolated or predominant ED (MALT MCL). We collected data on 127 patients with MALT MCL diagnosed from 1998 to 2015: 78 patients (61%) were male with a median age of 65 years. The involved sites include: upper airways + Waldeyer ring (40; 32%), gastrointestinal tract (32; 25%), ocular adnexa (17; 13%), oral cavity and salivary glands (17; 13%) and others (13; 1%); 7 patients showed multiple extranodal sites. The median follow-up was 80 months (range: 6-182), 5-year progression-free survival (PFS) was 45% (95% CI: 35-54) and 5-year overall survival (OS) was 71% (95% CI: 62-79). In an explorative setting, we compared MALT MCL with a group of 128 cMCL patients: MALT MCL patients showed a significantly longer PFS and OS compared with nodal cMCL; with a median PFS of 4.5 years vs 2.8 years (p = 0.001) and median OS of 9.8 years vs 6.9 years (p = 0.018), respectively. Patients with MALT MCL at diagnosis showed a more favorable prognosis and indolent course than classical nodal type. This clinical variant of MCL should be acknowledged to avoid possible over-treatment.
Identifiants
pubmed: 32072136
doi: 10.1097/HS9.0000000000000302
pii: HemaSphere-2019-0119
pmc: PMC7000480
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e302Informations de copyright
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Références
Blood. 2018 Jul 26;132(4):413-422
pubmed: 29769262
J Clin Oncol. 2009 Feb 1;27(4):511-8
pubmed: 19075279
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
Leukemia. 2001 Nov;15(11):1785-91
pubmed: 11681422
Cancer Res. 2012 Oct 15;72(20):5307-16
pubmed: 22915760
Am J Surg Pathol. 2006 Oct;30(10):1274-80
pubmed: 17001159
Curr Treat Options Oncol. 2017 Jul;18(7):45
pubmed: 28670664
Oncol Lett. 2017 Mar;13(3):1288-1292
pubmed: 28454248
Br J Haematol. 2017 Nov;179(3):430-438
pubmed: 28832957
Case Rep Pathol. 2017;2017:6749801
pubmed: 29435379
Blood. 2003 Jun 15;101(12):4975-81
pubmed: 12609845
Ann Oncol. 2017 Oct 1;28(10):2489-2495
pubmed: 28961827
Cancer. 2003 Feb 1;97(3):586-91
pubmed: 12548600
Br J Haematol. 2014 Jul;166(1):98-108
pubmed: 24684350
Blood. 2018 Oct 18;132(16):1647-1656
pubmed: 30154113
J Clin Oncol. 2016 Apr 20;34(12):1386-94
pubmed: 26926679
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Lancet Oncol. 2016 Mar;17(3):319-31
pubmed: 26899778
Blood. 2003 Apr 1;101(7):2489-95
pubmed: 12456507
Int J Hematol. 2012 Nov;96(5):631-7
pubmed: 23065471
Haematologica. 2011 Aug;96(8):1121-7
pubmed: 21508124